|Dr. Mark A. Velleca||CEO, Pres & Director||870.12k||3.08M||1964|
|Mr. James Stillman Hanson||Gen. Counsel||402.38k||N/A||1972|
|Mr. Terry L. Murdock||Sr. VP of Devel. Operations||541.59k||606.34k||1960|
|Mr. John Demaree||Chief Commercial Officer||359.35k||N/A||1967|
|Ms. Jennifer K. Moses||Chief Financial Officer||N/A||N/A||1975|
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
G1 Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.